Related Experiment Video
Updated: Aug 7, 2026
08:49
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Serotonin receptor blocking effect of SCH 23390
1Polish Academy of Sciences, Institute of Pharmacology, Kraków.
Pharmacology, Biochemistry, and Behavior
|March 1, 1989
Summary
Acute SCH 23390 administration blocks serotonin receptors, reducing head twitches. However, repeated SCH 23390 treatment leads to functional supersensitivity of these serotonin receptors.
Area of Science:
- Neuropharmacology
- Behavioral Neuroscience
Background:
- Serotonin system plays a crucial role in regulating various behaviors, including head twitching in rats.
- Understanding the effects of specific receptor antagonists on serotonin-mediated behaviors is essential for neuroscience research.
Purpose of the Study:
- To investigate the impact of acute and repeated administration of SCH 23390 on serotonin system-dependent head twitch behavior in rats.
- To explore the development of functional supersensitivity in central serotonin receptors following chronic SCH 23390 treatment.
Main Methods:
- Rats were administered varying doses of SCH 23390 (a dopamine D1 receptor antagonist with known effects on serotonin pathways) acutely and repeatedly.
- Head twitch behavior was quantified following administration of quipazine (a serotonin receptor agonist) and spontaneously.
- The effects of SCH 23390 were assessed in conjunction with cyproheptadine, a known serotonin receptor antagonist.
Main Results:
- A low, acute dose of SCH 23390 significantly reduced quipazine-induced head twitches.
- Repeated daily administration of SCH 23390 for 18 days led to an increase in both spontaneous and quipazine-induced head twitches.
- The enhanced head twitch response observed with repeated SCH 23390 administration was attenuated by co-administration of cyproheptadine.
Conclusions:
- Acute SCH 23390 administration acts to block central serotonin receptors, inhibiting head twitch behavior.
- Chronic administration of SCH 23390 induces functional supersensitivity of central serotonin receptors.
- These findings highlight the complex adaptive mechanisms within the serotonin system in response to pharmacological manipulation.
More Related Videos
07:30HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Related Concept Videos
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...